Measurement of harmful effects of aspirin
Systematic MEDLINE searches were carried out to determine i) magnitude of increase in harms caused by aspirin ii) age and sex-specific baseline rates of gastrointestinal bleeding, peptic ulcer and major extracranial bleeding ( Table 2 in the main text) iii) and the proportion of UGIC attributable to H. pylori infection in the UK general population. The estimates of mortality due to peptic ulcer and gastrointestinal bleeding were based on applying age-specific case-fatality rates (5% below and 10% above 70 years of age) to the respective incidence rates. Case-fatality rates were also derived from several studies [s1-7] identified through a systematic MEDLINE search.
Derivation of effect sizes (Table 3 in the main text) used for modelling
Effect sizes for cardiovascular disease:
All effect sizes used are directly taken from ATT Collaborators' review [s8].
Effect sizes for bleeding and ulcer harms:
Effect sizes derived as reported elsewhere [s9] .
Effect sizes for cancer:
Based on data presented in Table 1 (main text) General rules:
Data from case-control studies are based on a very large number of cancer incidence events, and these are generally consistent with data from RCTs [s10] . Therefore, derivation of effect sizes for cancer incidence is based on data from RCTs, case-control studies and cohort studies.
On the other hand, data from case-control studies for cancer mortality events are sparse Therefore, derivation of effect sizes for cancer mortality is based on data from RCTs and cohort studies. All effect sizes are assumed in steps of 5%.
Estimates for >5 years of aspirin use are considered where available Effect sizes are based on a non-weighted average of estimates from different study types.* Non-weighted average thus obtained is rounded to the closest 5% step on the side of unity. 
Bleeding and other side effects
Without a doubt increased bleeding is the most important side effect of aspirin [s9] . Haemorrhagic stroke, although rare, is the most serious and potentially fatal side effect. Estimates suggest a relative increase of 32-36% in haemorrhagic strokes in aspirin users from a baseline rate of 0.03%/year [s8, 11-14] .
Much commoner are the extracranial (predominantly gastro-intestinal) bleeds, where the risk for major events is increased by about 30-70% from an overall baseline risk of 0.7 per 1000 per year [s8, 11, 12, 14-16] with low or standard-dose aspirin treatment [s9] . Absolute risks differ substantially across the population ( Table 2 in the main text). Aspirin-related gastro-intestinal bleeding is frequently a result of either aspirin-induced acute erosive gastritis or haemorrhagic complication of peptic ulcer. Different studies [s8, 17-20] report different baseline major bleeding rates due to differences in the definitions and populations. We use rates estimated from ATT data and the basis for this is fully discussed elsewhere [s9] . The baseline risk of uncomplicated peptic ulcer in the general population increases from 0.5 per 1000 per year in women and 0.6 per 1000 per year in men aged 50-54 years to 1.0 and 1. Aspirin use after cancer diagnosis, effect on metastasis and survival.
Aspirin appears to have an impact on mortality that exceeds its effect on incidence [s31] . Aspirin may reduce metastatic spread through its effect on platelets [s32, 33], but it may also act through other mechanisms [s34-37] . RCTs show larger effect sizes for cancer mortality reduction than those for cancer incidence reduction [s38] . RCTs have also shown a lower proportion of cancers with metastases at presentation in those taking aspirin and lower propensity to develop metastases in those who continue aspirin after cancer diagnosis [s39] . Observational studies in breast cancer [s40], and colorectal cancer [s41, 42] have shown similar observations of reduced metastasis and improved survival in patients taking or continuing aspirin after the diagnosis of cancer. Recent evidence from the Nurses' Health Study and the Health Professionals Follow-up Study suggests that PIK3CA mutation may be a predictive biomarker for aspirin efficacy in adjuvant treatment [s43] . Therapeutic use of aspirin in colorectal cancer is currently being investigated in the ASCOLT trial [s44] whereas the Big A trial [s45] will investigate aspirin as an adjuvant treatment in non-small cell lung cancer. Another trial (ADD-Aspirin) is being set up in the UK to investigate role of aspirin in adjuvant treatment of colorectal, gastro-oesophageal, breast and prostate cancers [s37] .
